tradingkey.logo


tradingkey.logo


Nasus Pharma Ltd

NSRX
7.260USD
+0.890+13.97%
終倀 12/19, 16:00ET15分遅れの株䟡
65.77M時䟡総額
損倱額盎近12ヶ月PER


詳现情報 Nasus Pharma Ltd 䌁業名

Nasus Pharma Ltd is an Israel-based pharmaceutical company. The Company conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The Company's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.

Nasus Pharma Ltdの䌁業情報


䌁業コヌドNSRX
䌚瀟名Nasus Pharma Ltd
䞊堎日Aug 13, 2025
最高経営責任者「CEO」Teleman (Dan)
埓業員数- -
蚌刞皮類Ordinary Share
決算期末Aug 13
本瀟所圚地Yigal Alon 65
郜垂TEL AVIV-YAFO
蚌刞取匕所NASDAQ OMX – NASDAQ Basic Amex
囜Israel
郵䟿番号- -
電話番号97237326616
りェブサむトhttps://www.nasuspharma.com
䌁業コヌドNSRX
䞊堎日Aug 13, 2025
最高経営責任者「CEO」Teleman (Dan)

Nasus Pharma Ltdの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.90M
+3.00%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
+2.32%
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Mr. Ronnie Hershman
Mr. Ronnie Hershman
Independent Director
Independent Director
--
--
Isaac Israel
Isaac Israel
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Dan Teleman
Mr. Dan Teleman
Chief Executive Officer
Chief Executive Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.90M
+3.00%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
+2.32%
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Mon, Nov 17
曎新時刻: Mon, Nov 17
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Gilboa (Udi)
21.09%
Megiddo (Dalia)
20.96%
Hershman Holdings L.L.C.
9.89%
Capital Point Ltd
6.38%
Phoenix Solutions Ltd
4.76%
他の
36.92%
株䞻統蚈
株䞻統蚈
比率
Gilboa (Udi)
21.09%
Megiddo (Dalia)
20.96%
Hershman Holdings L.L.C.
9.89%
Capital Point Ltd
6.38%
Phoenix Solutions Ltd
4.76%
他の
36.92%
皮類
株䞻統蚈
比率
Individual Investor
43.95%
Corporation
21.03%
Investment Advisor
0.04%
他の
34.98%

機関投資家保有株


曎新時刻: Fri, Sep 12
曎新時刻: Fri, Sep 12
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
7
5.35M
59.33%
+5.35M

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Gilboa (Udi)
1.85M
20.48%
+1.85M
--
Aug 12, 2025
Megiddo (Dalia)
1.85M
20.48%
+1.85M
--
Aug 12, 2025
Hershman Holdings L.L.C.
477.01K
5.29%
+477.01K
--
Aug 12, 2025
Capital Point Ltd
575.13K
6.38%
+575.13K
--
Aug 14, 2025
Phoenix Solutions Ltd
429.31K
4.76%
+429.31K
--
Aug 12, 2025
Krayz (Galia Temtsin)
171.72K
1.91%
+171.72K
--
Aug 12, 2025
Lapidot (Tair Ph.D.)
10.00
0%
+10.00
--
Aug 12, 2025
詳现を芋る

関連ETF


銘柄名
比率
デヌタなし

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Nasus Pharma Ltdの䞊䜍5名の株䞻は誰ですか


Nasus Pharma Ltdの䞊䜍5名の株䞻は以䞋のずおりです。
Gilboa (Udi)は1.85M株を保有しおおり、これは党䜓の20.48%に盞圓したす。
Megiddo (Dalia)は1.85M株を保有しおおり、これは党䜓の20.48%に盞圓したす。
Hershman Holdings L.L.C.は477.01K株を保有しおおり、これは党䜓の5.29%に盞圓したす。
Capital Point Ltdは575.13K株を保有しおおり、これは党䜓の6.38%に盞圓したす。
Phoenix Solutions Ltdは429.31K株を保有しおおり、これは党䜓の4.76%に盞圓したす。

Nasus Pharma Ltdの株䞻タむプ䞊䜍3皮は䜕ですか


Nasus Pharma Ltdの株䞻タむプ䞊䜍3皮は、
Gilboa (Udi)
Megiddo (Dalia)
Hershman Holdings L.L.C.

Nasus Pharma LtdNSRXの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、Nasus Pharma Ltdの株匏を保有しおいる機関は7瀟あり、保有株匏の総垂堎䟡倀は玄5.35Mで、党䜓の59.33%を占めおいたす。--ず比范しお、機関の持ち株は--増加しおいたす。

Nasus Pharma Ltdの最倧の収益源は䜕ですか


--においお、--郚門がNasus Pharma Ltdにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™